Mangoceuticals (MGRX) Net Income towards Common Stockholders (2023 - 2026)

Mangoceuticals (MGRX) has 4 years of Net Income towards Common Stockholders data on file, last reported at -$3.7 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 27.98% year-over-year to -$3.7 million; the trailing twelve-month figure through Mar 2026 stood at -$22.7 million (down 93.22% YoY), and the FY2025 full-year result was -$21.8 million, down 129.47% from the prior year.
• Net Income towards Common Stockholders advanced to -$3.7 million in Q1 2026, from -$5.7 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$1.8 million in Q3 2023 to a low of -$7.9 million in Q3 2025.
• A 4-year average of -$3.5 million and a median of -$2.6 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders slumped 245.02% in 2025 and grew 27.98% in 2026, its largest moves.
• Tracing MGRX's Net Income towards Common Stockholders over 4 years: stood at -$2.6 million in 2023, then increased by 24.13% to -$1.9 million in 2024, then tumbled by 193.06% to -$5.7 million in 2025, then jumped by 35.25% to -$3.7 million in 2026.
• Business Quant data shows MGRX's Net Income towards Common Stockholders at -$3.7 million in Q1 2026, -$5.7 million in Q4 2025, and -$7.9 million in Q3 2025.